Portfolio Companies

Restricted

Summary

Novel neuroprotective therapeutics for the treatment of stroke, traumatic brain injury (TBI), concussion, and neurodegenerative diseases.

Documents

Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004

Astrocyte Pharmaceuticals 2022 Q2 Investor Update

Astrocyte Pharmaceuticals 2022 Q1 Investor Update

Astrocyte Pharmaceuticals 2021 Q4 Investor Update

Astrocyte awarded major grant for brain injury Astrocyte Pharmaceuticals 2021 Q2 Investor Update

Astrocyte Investor Welcome

Astrocyte Pharmaceuticals 2021 [ Read more… ]

2022-11-15T16:25:46+00:00November 23rd, 2020|

Restricted

Summary

A mesh-free approach for pelvic floor fixation for Pelvic Organ Prolapse (POP), which is a painful, debilitating medical condition that occurs when the normal support of the vagina is lost, resulting in the “sagging” or dropping of the female pelvic organs.

Documents

Dec 16, 2021 Investor Call – 2021 Q4 Investor Update presentation v4 FINAL (slides). Link to presentation.

2021 Q3 Investor Update FINAL

LiNA Medical USA and FEMSelect Announce National Launch of the EnPlace® Pelvic Floor Ligament Fixation System (Aug 2021)

FemSelect 2021 Q2 Investor Update FINAL presentation

[ Read more… ]

2022-11-15T16:03:53+00:00November 22nd, 2019|

Restricted

Summary

New View Surgical – novel VisionPort™ System is the first surgeon-controlled, multi-camera laparoscopic visualization system.

Documents

New View Surgical Q3 2022 Update

New View Surgical 2022 Q2 Update

New View Surgical 2022 Q1 Financial Statements and Management Notes

New View Surgical 2022 Q1 Updates

New View Surgical – Q4 2021 Financial Statements and Management Notes

New View Surgical – Q4 2021 Update

New View Surgical Q3 2021 Financial Statements and Management Notes

Website

https://newviewsurg.com/

2022-11-29T14:24:31+00:00November 22nd, 2019|

Restricted

Summary

Healionics is a clinical stage company addressing the critical need for improved means of dialysis access in patients with kidney failure. Healionics’ STARgraft vascular graft (artificial blood vessel) resists the problems of occlusion and infection suffered by current devices. The company is also developing a product pipeline based on its platform STAR® biomaterial, which has a unique ability to prevent both scarring and infection in a wide variety of other implantable device applications.

Documents

Healionics 2022 Q3 Update

Healionics 2022 Q2 Update

Healionics 2022 Q1 Update

Healionics 2021 Q4 Update

Healionics [ Read more… ]

2022-11-15T16:05:18+00:00February 5th, 2019|

Restricted

Summary

Developing next generation antivirals that engage the patient’s own immunity to naturally defend against viral infection without the emergence of drug resistance.

Documents

Evrys Financials 2021 Q3

Evrys Bio Financials 2020 Q3

Evrys Bio Financials 2020 Q2

Evrys Bio Financials 2020 Q1

Evrys Annual Report 2019

Forge Financials 2018 Q3

Forge Financials 2018 Q2

Forge Annual Report 2018

Forge Financials 2018 Q1

Forge Annual Report 2017

Forge Financials 2017 Q3

Forge Annual Report 2016

Website https://evrysbio.com/ [ Read more… ]

2022-11-15T15:08:30+00:00June 27th, 2016|

Restricted

Summary

Cerus Endovascular is engaged in the design and development of highly differentiated and proprietary interventional neuroradiology (INR) devices and delivery systems, which it believes will represent the next generation in the minimally invasive treatment of neurovascular diseases, particularly intracranial aneurysms.

Documents

Cerus Shareholder Letter – June 2022

Cerus Endovascular Receives US FDA 510(k) Clearance of its 027 Micro-catheter 

Tiny device with a titanic impact: How neurosurgeons are treating one of the most dangerous brain aneurysms – From MedicalXpress

Cerus Shareholder Letter 13 December 2021

Cerus Endovascular – Shareholder [ Read more… ]

2022-11-15T15:57:50+00:00June 21st, 2013|
Go to Top